The European Medicines Agency said on Friday it had recommended cancer drug DepoCyte be recalled in Europe, where suitable alternative treatments are available, due to sterility concerns at a U.S. plant operated by Pacira Pharmaceuticals. A recent inspection carried out jointly by France and Britain at Pacira’s manufacturing site in San Diego identified a number of manufacturing deficiencies related to a lack of adequate sterility assurance in the manufacturing process.
